Stockscreener 앱 받기
0.4981
3.29%
-0.017
Bioaffinity Technologies Inc 주식(BIAF)의 최신 뉴스
bioAffinity Technologies streamlines lung cancer detection test By Investing.com - Investing.com Canada
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost - BioSpace
bioAffinity Technologies streamlines lung cancer detection test - Investing.com
Bioaffinity Technologies Increases Efficiency Of Cypath Lung Test - marketscreener.com
Revolutionary Lung Cancer Detection Test Achieves 92% Accuracy While Slashing Costs by 25% - Stock Titan
ASP Isotopes and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Corsicana Daily Sun
bioAffinity Technologies Board Member Announces Departure - TipRanks
CyPath Lung Helped Detect Breast Cancer Recurrence - Medical Product Outsourcing
Bioaffinity Technologies Files For Resale Of Up To 3.0 Million Shares Of Common Stock By Selling StockholdersSEC Filing - MarketScreener
bioAffinity Technologies Reports Record Revenue for 2024 - TipRanks
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues - Yahoo Finance
Earnings roundup: Usio back in the black; losses widen at bioAffinity, Wytec - San Antonio Express-News
bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Joplin Globe
bioAffinity Technologies Stock Price, Quotes and Forecasts | NASDAQ:BIAF - Benzinga
Best Biotech Stocks To Follow Today – April 1st - Defense World
Biotech stock bioAffinity Technologies, Inc. (NASDAQ: BIAF) Makes NASDAQ Top Percentage Gainer on News - Investorideas.com
Take off with BioAffinity Technologies Inc (BIAF): Get ready for trading - Sete News
bioAffinity Technologies Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
bioAffinity Technologies (NASDAQ:BIAF) Given Hold Rating at Maxim Group - Defense World
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Lung cancer spit test fast-tracks a San Antonio biotech company for growth - MSN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Nasdaq Surges 1%; US Construction Spending Rises In February - Benzinga
Dow Dips Over 400 Points; ISM Manufacturing PMI Falls In March - Benzinga
What's Going On With BioAffinity Shares Tuesday? - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
bioAffinity Technologies stock hits 52-week low at $0.25 By Investing.com - Investing.com South Africa
bioAffinity Technologies, Inc. SEC 10-K Report - TradingView
bioAffinity Technologies earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
bioAffinity posts 270% revenue rise with Medicare coverage - Investing.com
bioAffinity Technologies stock hits 52-week low at $0.25 - Investing.com
bioAffinity posts 270% revenue rise with Medicare coverage By Investing.com - Investing.com India
Record-Breaking 270% Revenue Surge: bioAffinity's Growth Story Takes Unexpected Turn - Stock Titan
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 - The Joplin Globe
Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer - BioSpace
BIOAFFINITY TECHNOLOGIES Earnings Preview: Recent $BIAF Insider Trading, Hedge Fund Activity, and More - Nasdaq
Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer - Business Wire
bioAffinity Technologies (NASDAQ:BIAFW) Shares Down 24.3% – Here’s What Happened - Defense World
bioAffinity stock hits 52-week low at $0.26 amid market challenges - Investing.com Australia
BioAffinity Technologies Inc (BIAF): An Important Analyst Insights - Stocks Register
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence - BioSpace
bioAffinity stock hits 52-week low at $0.26 amid market challenges By Investing.com - Investing.com South Africa
bioAffinity Technologies Cutting Jobs to Save $4 Million in Operating Costs - MPO-mag
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million - Business Wire
Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer - Joplin Globe
0.05%
0.35%
자본화:
|
볼륨(24시간):